187 related articles for article (PubMed ID: 8168119)
1. Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice.
Gazit Z; Kedar E
Cancer Immunol Immunother; 1994 Apr; 38(4):243-52. PubMed ID: 8168119
[TBL] [Abstract][Full Text] [Related]
2. Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.
Gazit Z; Weiss DW; Shouval D; Yechezkeli M; Schirrmacher V; Notter M; Walter J; Kedar E
Cancer Immunol Immunother; 1992; 35(2):135-44. PubMed ID: 1596937
[TBL] [Abstract][Full Text] [Related]
3. Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.
Stewart LS; Sewell HF; Thomson AW
Clin Exp Immunol; 1990 Mar; 79(3):416-23. PubMed ID: 2317946
[TBL] [Abstract][Full Text] [Related]
4. cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro.
Okamoto M; Kasetani H; Kaji R; Goda H; Ohe G; Yoshida H; Sato M
Cancer Immunol Immunother; 1998 Dec; 47(4):233-41. PubMed ID: 9875677
[TBL] [Abstract][Full Text] [Related]
5. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
[TBL] [Abstract][Full Text] [Related]
6. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
7. [Effects of pretreatment with lentinan or krestin on antitumor effector cell activities suppressed by cyclophosphamide].
Yang ZB
Hokkaido Igaku Zasshi; 1994 Jan; 69(1):137-45. PubMed ID: 8119654
[TBL] [Abstract][Full Text] [Related]
8. Lymphokine-activated killer cells in rats: generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells.
Sarneva M; Vujanovic NL; Van den Brink MR; Herberman RB; Hiserodt JC
Cell Immunol; 1989 Feb; 118(2):448-57. PubMed ID: 2910504
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor beta 1 (TGF-beta 1) produced in tumour tissue after chemotherapy acts as a lymphokine-activated killer attractant.
Kuramitsu Y; Nishibe M; Kobayashi M; Togashi Y; Yuan L; Takizawa M; Okada F; Hosokawa M
Br J Cancer; 1996 Jul; 74(2):274-9. PubMed ID: 8688335
[TBL] [Abstract][Full Text] [Related]
10. Effect of ASTA-Z 7575 (INN Maphosphamide) on human lymphokine-activated killer cell induction.
Singh KP; Gupta RK; Shau H; Ray PK
Immunopharmacol Immunotoxicol; 1993 Nov; 15(5):525-38. PubMed ID: 8301017
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human interleukin-1 alpha: a potent bio-immunomodifier in vivo in immunosuppressed mice induced by cyclophosphamide, retroviral infection and surgical stress.
Shen RN; Wu B; Lu L; Kaiser HE; Broxmeyer HE
In Vivo; 1994; 8(1):59-63. PubMed ID: 8054512
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer cells and aging in mice: significance for defining the precursor cell.
Kawakami K; Bloom ET
Mech Ageing Dev; 1987 Dec; 41(3):229-40. PubMed ID: 2892985
[TBL] [Abstract][Full Text] [Related]
13. Induction of lymphokine-activated killer activity in mice by prothymosin alpha.
Baxevanis CN; Gritzapis AD; Dedoussis GV; Papadopoulos NG; Tsolas O; Papamichail M
Cancer Immunol Immunother; 1994 Apr; 38(4):281-6. PubMed ID: 8168124
[TBL] [Abstract][Full Text] [Related]
14. Effective in vivo induction of lymphokine-activated killer (LAK) cells by pretreatment with a streptococcal preparation, OK-432.
Shimoda K; Saito T; Kobayashi M; Nomoto K
Biotherapy; 1992; 5(1):63-9. PubMed ID: 1389903
[TBL] [Abstract][Full Text] [Related]
15. Induction of lymphokine-activated killer cells from nude mouse spleen cells by interleukin-4.
Tunru IS; Suzuki H; Kobayashi M
Experientia; 1993 Jan; 49(1):76-9. PubMed ID: 7679079
[TBL] [Abstract][Full Text] [Related]
16. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
[TBL] [Abstract][Full Text] [Related]
17. Strain- and age-dependent natural and activated in vitro cytotoxicity in athymic nude mice.
Radzikowski C; Rygaard J; Budzynski W; Stenvang JP; Schou M; Vangsted A; Zeuthen J
APMIS; 1994 Jul; 102(7):481-8. PubMed ID: 7917216
[TBL] [Abstract][Full Text] [Related]
18. Effector and precursor phenotypes of lymphokine-activated killer cells in mice with severe combined immunodeficiency (scid) and athymic (nude) mice.
Hasui M; Saikawa Y; Miura M; Takano N; Ueno Y; Yachie A; Miyawaki T; Taniguchi N
Cell Immunol; 1989 Apr; 120(1):230-9. PubMed ID: 2784720
[TBL] [Abstract][Full Text] [Related]
19. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of IL-2-mediated protection against GVHD in mice. II. Protection occurs independently of NK/LAK cells.
Sykes M; Abraham VS
Transplantation; 1992 May; 53(5):1063-70. PubMed ID: 1533968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
